What is HC Wainwright’s Forecast for ACAD Q1 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will earn $0.10 per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.24 EPS and FY2029 earnings at $2.32 EPS.

A number of other equities research analysts have also recently issued reports on the stock. StockNews.com cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday. Finally, Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $19.60 on Friday. ACADIA Pharmaceuticals has a 52-week low of $14.15 and a 52-week high of $24.53. The company has a 50-day moving average of $18.37 and a two-hundred day moving average of $16.81. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 25.13 and a beta of 0.37.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $47,000. GF Fund Management CO. LTD. bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $64,000. Quest Partners LLC raised its stake in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares during the last quarter. Finally, KBC Group NV raised its stake in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.